$XBI $91.77 | +2.13%
Covid Updates
$AZN +2.6% Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19 source
Pipeline Updates
$TARA +3.7% Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer source
$AMRX +0.7% Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting source
$ARWR +3.4% Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases source
$JAZZ +0.7% Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors source
$MRNA +0.5% Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day source
$FENC -6.1% FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARKâ„¢ source
$AZN +2.6% Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer source
Business Updates
$HALO +3.0% Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology source
$APLS -6.2% Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock source
Posted by JM